• About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • Documents
  • news
    • news
    • Press releases
    • Blog
    • Press Coverage
    • Events
  • Login
  • Contact

o2h-ventures

  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • Documents
  • news
    • news
    • Press releases
    • Blog
    • Press Coverage
    • Events
  • Login
  • Contact

Don’t invest unless you’re prepared to lose all your money invested. This is a high risk investment. You could lose all the money you invest and are unlikely to be protected if something goes wrong. Take 2 mins to learn more

July 2022, o2h Ventures Fund Newsletter, Deals executed in Alevin Therapeutics, Neurofenix, Five Alarm Bio
Aug 1 2022

Amid the ongoing debate about who will be the next Prime Minister of the UK; it will be important that whoever eventually wins continues to invest in building the UK Biotech ecosystem.

Reflecting back on the last month for o2h Ventures, we are pleased to announce the successful closing of the o2h human health SEIS Fund. We executed three deals in the last month with one investment in the SEIS Fund and two investments in the KI EIS Fund. 

Industry Update:

According to the latest report published by UK Business Angels Association published July 2022, there is a  knowledge gap among investors in ‘science and innovation’ which is compounded by the lack of progressive angel groups around university clusters that hinders investments due to the technical assessments that are required to invest. 

To check out the entire report, Click here.

This is where we believe it makes sense to invest in specialist funds such as o2h Ventures which are able to assess the validity of the science at an early stage to make an educated assessment of the viability of the biotechnology and the business. See our KI EIS Fund.. 

Deals Executed:

  • Alevin Therapeutics – We lead an investment close to £1 Million from our SEIS and EIS fund, alongside co-investment from the University of Nottingham’s Invention Fund, into Alevin Therapeutics. The Nottingham University spin-out aims to develop assets for therapeutic applications based on their RGD Integrin platform; in particular idiopathic pulmonary fibrosis (IPF), liver and kidney disease and cancer. The most advanced programme is close to a development candidate which we seek to take forward as an inhaled IPF drug. The molecule targets ɑvβ6 which very recently @pliant published Phase II clinical validating the target for their oral molecule. 
  • Neurofenix – We made a follow-on investment from our Knowledge Intensive (KI) Human Health EIS fund into Neurofenix: a revenue-generating digital therapeutics company developing technologies to support patients rehabilitating from Stroke. Earlier, we invested in their seed round and since then the company undoubtedly has made significant progress on both developing their product and finding a product-market fit. The founders have also moved themselves out to the USA to engage with the biggest market (a smart move!).
  • Five Alarm Bio – From our SEIS investment, we invested in Five Alarm Bio, a drug discovery company based in Cambridge, UK that focuses on novel approaches to anti-aging, with a broad potential for therapeutic application. Five Alarm Bio recently won a grant  BioMedical Catalyst grant of £360k and also generated data for their lead compound in collaboration with Magnitude Biosciences showing clear and impressive delay in ageing in C. elegans above and beyond many other compounds tested in the ageing research space.

We will now follow up with portfolio companies and HMRC to issue the EIS5 Certificates in the next few weeks for our investors that invested in the o2h human health KI Fund closed on 5th April 2021 and 30th October 2021 respectively as we have now deployed more than 90% of these funds. 

Please feel free to reach out to us on invest@o2h.com to discuss the above updates further or in case of any queries or questions.

Connect with us
  • linkedin
  • twitter
  • instagram
  • facebook
  • youtube
o2h-ventures
related stories
  • Oct 2022, o2h Ventures Fund Newsletter, KI EIS Closing, EISA events 1 November, 2022
  • Aug-Sept 2022, o2h Ventures Fund Newsletter, fifty percent of our companies led by female and more portfolio updates 30 September, 2022
  • July 2022, o2h Ventures Fund Newsletter, Deals executed in Alevin Therapeutics, Neurofenix, Five Alarm Bio 1 August, 2022
o2h-ventures
The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years.
Useful Links
  • About Us
  • Blog
  • Documents Centre
  • Contact Us
  • Team
News
  • Oct 2022, o2h Ventures Fund Newsletter, KI EIS Closing, EISA events
  • Aug-Sept 2022, o2h Ventures Fund Newsletter, fifty percent of our companies led by female and more portfolio updates
  • July 2022, o2h Ventures Fund Newsletter, Deals executed in Alevin Therapeutics, Neurofenix, Five Alarm Bio
Connect with us
  • linkedin
  • twitter
  • instagram
  • facebook
© 2023 o2h ventures
  • Privacy Policy
  • Blog
  • Contact us
o2h ventures Limited is regulated and authorised by the Financial Conduct Authority (FRN 812245). Capital at risk, only suitable for high net worth and sophisticated investors

Risk Information

Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk

What are the key risks?

1 – You could lose all the money you invest

• If the business you invest in fails, you are likely to lose 100% of the money you invest. Most start-up businesses fail.

2 – You are unlikely to be protected if something goes wrong

• Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker here. (https://www.fscs.org.uk/check/investment-protection-checker)

• Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated firm, FOS may be able to consider it. Learn more about FOS protection here. (https://www.financial-ombudsman.org.uk/consumers)

3 – You won’t get your money back quickly

• Even if the business you invest in is successful, it may take several years to get your money back. You are unlikely to be able to sell your investment early.

• The most likely way to get your money back is if the business is bought by another business or lists its shares on an exchange such as the London Stock Exchange. These events are not common.

• If you are investing in a start-up business, you should not expect to get your money back through dividends. Start-up businesses rarely pay these.

4 – Don’t put all your eggs in one basket

• Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well.

• A good rule of thumb is not to invest more than 10% of your money in high-risk investments (https://www.fca.org.uk/investsmart/5-questions-ask-you-invest)

5 – The value of your investment can be reduced

• The percentage of the business that you own will decrease if the business issues more shares. This could mean that the value of your investment reduces, depending on how much the business grows. Most start-up businesses issue multiple rounds of shares.

• These new shares could have addition rights that your shares don’t have, such as the right to receive a fixed dividend, which could further reduce your chances of getting a return on your investment.

If you are interested in learning more about how to protect yourself, visit the FCA’s website here (https://www.fca.org.uk/investsmart)